Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Non-Hodgkin 24Lymphoma, Follicular 17Lymphoma 14Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, B-Cell 9Neoplasms 5Lymphoma, B-Cell, Marginal Zone 4Melanoma 3Leukemia 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Leukemia, B-Cell 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Tumor Lysis Syndrome 1Solid Cancers 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Oncology Patients Receiving Chemotherapy 1Neoplasm Metastasis 1Mesothelioma 1Mature B-cell Malignancies 1

Interventions

tofacitinib 7ibrutinib 6ruxolitinib 3ofatumumab 3asciminib 3Imatinib Mesylate 3Dasatinib 3nilotinib 2bosutinib 2Rituximab 2Oxycodone 2Naloxone 2KW-2478 2sodium luminolate 1oblimersen 1obinutuzumab 1mocetinostat 1milatuzumab 1ixekizumab 1fenebrutinib 1canakinumab 1belumosudil 1baricitinib 1axatilimab 1abexinostat 1Vision, Ocular 1Sofosbuvir 1Sirolimus 1Saline Solution 1Ribavirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bronchiolitis Obliterans Syndrome × obinutuzumab × Clear all
NCT01680991 2016-04-25

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Hoffmann-La Roche

Phase 1 Completed
48 enrolled 27 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡